| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 122 | 2024 | 11230 | 6.960 |
Why?
|
| Genes, BRCA1 | 55 | 2020 | 756 | 6.840 |
Why?
|
| Genes, BRCA2 | 47 | 2020 | 593 | 6.410 |
Why?
|
| BRCA2 Protein | 41 | 2022 | 803 | 5.220 |
Why?
|
| BRCA1 Protein | 43 | 2022 | 1156 | 5.090 |
Why?
|
| Genetic Predisposition to Disease | 149 | 2024 | 18068 | 3.680 |
Why?
|
| Ovariectomy | 21 | 2016 | 613 | 3.660 |
Why?
|
| Breast Neoplasms | 125 | 2023 | 21188 | 3.030 |
Why?
|
| Ovarian Neoplasms | 49 | 2024 | 4919 | 3.030 |
Why?
|
| Neoplasms | 69 | 2024 | 22389 | 2.560 |
Why?
|
| Prostate-Specific Antigen | 30 | 2024 | 2487 | 2.400 |
Why?
|
| Heterozygote | 52 | 2022 | 2798 | 2.190 |
Why?
|
| Cytochrome P-450 Enzyme System | 16 | 2014 | 423 | 2.170 |
Why?
|
| Polymorphism, Single Nucleotide | 85 | 2024 | 16053 | 2.050 |
Why?
|
| Germ-Line Mutation | 32 | 2022 | 1887 | 1.830 |
Why?
|
| Mutation | 72 | 2022 | 30266 | 1.680 |
Why?
|
| Genotype | 91 | 2019 | 13048 | 1.630 |
Why?
|
| Endometrial Neoplasms | 21 | 2023 | 1386 | 1.510 |
Why?
|
| Health Status Disparities | 12 | 2023 | 1886 | 1.480 |
Why?
|
| Prostatectomy | 17 | 2022 | 1841 | 1.430 |
Why?
|
| Genome-Wide Association Study | 44 | 2024 | 12801 | 1.420 |
Why?
|
| Early Detection of Cancer | 21 | 2024 | 3238 | 1.380 |
Why?
|
| Residence Characteristics | 8 | 2023 | 2121 | 1.340 |
Why?
|
| Genetic Variation | 33 | 2021 | 6611 | 1.320 |
Why?
|
| Prostate | 14 | 2024 | 1781 | 1.290 |
Why?
|
| Glutathione Transferase | 12 | 2011 | 564 | 1.280 |
Why?
|
| Social Class | 7 | 2023 | 2009 | 1.260 |
Why?
|
| Genetics, Population | 13 | 2024 | 944 | 1.230 |
Why?
|
| Humans | 467 | 2024 | 768970 | 1.220 |
Why?
|
| Alleles | 43 | 2024 | 6901 | 1.140 |
Why?
|
| Case-Control Studies | 85 | 2024 | 22296 | 1.130 |
Why?
|
| Cytochrome P-450 CYP3A | 15 | 2012 | 118 | 1.120 |
Why?
|
| Africa South of the Sahara | 10 | 2024 | 753 | 1.110 |
Why?
|
| Mastectomy | 7 | 2022 | 1850 | 1.070 |
Why?
|
| Polymorphism, Genetic | 32 | 2013 | 4251 | 1.030 |
Why?
|
| Healthcare Disparities | 11 | 2024 | 3421 | 0.960 |
Why?
|
| Estrogen Replacement Therapy | 7 | 2022 | 1209 | 0.950 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 6 | 2012 | 246 | 0.950 |
Why?
|
| Receptor, Melanocortin, Type 1 | 6 | 2015 | 74 | 0.940 |
Why?
|
| Genomics | 12 | 2023 | 5928 | 0.920 |
Why?
|
| Gene Frequency | 30 | 2024 | 3626 | 0.910 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 2 | 2023 | 30 | 0.910 |
Why?
|
| Male | 211 | 2024 | 365203 | 0.900 |
Why?
|
| Risk Factors | 121 | 2024 | 74976 | 0.880 |
Why?
|
| Middle Aged | 198 | 2024 | 223737 | 0.870 |
Why?
|
| Risk Reduction Behavior | 11 | 2024 | 1119 | 0.860 |
Why?
|
| Biomedical Research | 9 | 2024 | 3463 | 0.820 |
Why?
|
| Multiple Myeloma | 8 | 2024 | 5196 | 0.800 |
Why?
|
| Environment | 3 | 2023 | 1122 | 0.770 |
Why?
|
| Community-Institutional Relations | 1 | 2023 | 209 | 0.770 |
Why?
|
| Haplotypes | 15 | 2024 | 2725 | 0.760 |
Why?
|
| Health Services Accessibility | 10 | 2024 | 5522 | 0.760 |
Why?
|
| Genetic Markers | 18 | 2012 | 2604 | 0.760 |
Why?
|
| SEER Program | 5 | 2024 | 1473 | 0.750 |
Why?
|
| Periodicals as Topic | 5 | 2011 | 1470 | 0.750 |
Why?
|
| Germ Cells | 4 | 2023 | 644 | 0.740 |
Why?
|
| Genetic Testing | 19 | 2024 | 3591 | 0.730 |
Why?
|
| Whiplash Injuries | 2 | 2013 | 15 | 0.710 |
Why?
|
| Aged | 141 | 2024 | 171786 | 0.710 |
Why?
|
| Hot Flashes | 3 | 2014 | 330 | 0.700 |
Why?
|
| Female | 239 | 2024 | 397515 | 0.700 |
Why?
|
| Prognosis | 43 | 2023 | 30046 | 0.700 |
Why?
|
| Catechol O-Methyltransferase | 4 | 2012 | 251 | 0.690 |
Why?
|
| Neoplasm Proteins | 16 | 2016 | 3608 | 0.690 |
Why?
|
| Community-Based Participatory Research | 1 | 2022 | 223 | 0.690 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2020 | 81 | 0.670 |
Why?
|
| Estrogens | 8 | 2022 | 1536 | 0.660 |
Why?
|
| Odds Ratio | 37 | 2019 | 9684 | 0.650 |
Why?
|
| Receptors, Progesterone | 10 | 2014 | 1159 | 0.640 |
Why?
|
| Incidence | 35 | 2024 | 21547 | 0.630 |
Why?
|
| Adult | 151 | 2024 | 223851 | 0.620 |
Why?
|
| Pennsylvania | 8 | 2021 | 615 | 0.620 |
Why?
|
| Oncogene Proteins, Fusion | 3 | 2020 | 1616 | 0.620 |
Why?
|
| Molecular Epidemiology | 7 | 2010 | 473 | 0.620 |
Why?
|
| Epidemiology | 4 | 2019 | 278 | 0.610 |
Why?
|
| Carcinoma | 8 | 2021 | 2340 | 0.600 |
Why?
|
| Population Surveillance | 6 | 2019 | 2597 | 0.600 |
Why?
|
| Melanoma | 20 | 2015 | 5709 | 0.580 |
Why?
|
| Epidemiologic Studies | 4 | 2013 | 677 | 0.580 |
Why?
|
| Mixed Function Oxygenases | 4 | 2000 | 265 | 0.570 |
Why?
|
| Pathology, Molecular | 4 | 2022 | 329 | 0.560 |
Why?
|
| Arylsulfotransferase | 5 | 2010 | 27 | 0.550 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 3 | 2024 | 179 | 0.540 |
Why?
|
| Risk Assessment | 33 | 2024 | 24333 | 0.540 |
Why?
|
| Health Facilities | 2 | 2022 | 577 | 0.530 |
Why?
|
| Primary Prevention | 4 | 2018 | 1187 | 0.510 |
Why?
|
| Publishing | 3 | 2008 | 837 | 0.510 |
Why?
|
| DNA, Mitochondrial | 3 | 2017 | 872 | 0.500 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 948 | 0.500 |
Why?
|
| Propensity Score | 4 | 2022 | 1968 | 0.490 |
Why?
|
| Cytochrome P-450 CYP1A2 | 3 | 2012 | 68 | 0.490 |
Why?
|
| Socioeconomic Factors | 10 | 2024 | 7861 | 0.490 |
Why?
|
| Endoribonucleases | 2 | 2008 | 231 | 0.480 |
Why?
|
| Skin Neoplasms | 16 | 2015 | 5864 | 0.470 |
Why?
|
| Genetic Association Studies | 12 | 2021 | 2748 | 0.470 |
Why?
|
| Precancerous Conditions | 5 | 2024 | 985 | 0.470 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2022 | 3554 | 0.470 |
Why?
|
| Philadelphia | 7 | 2013 | 271 | 0.460 |
Why?
|
| Jews | 7 | 2012 | 359 | 0.460 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2022 | 9442 | 0.460 |
Why?
|
| Risk | 27 | 2022 | 9621 | 0.460 |
Why?
|
| Genetic Linkage | 16 | 2004 | 2342 | 0.460 |
Why?
|
| United States | 49 | 2024 | 73186 | 0.450 |
Why?
|
| Fallopian Tubes | 3 | 2010 | 179 | 0.450 |
Why?
|
| Polymerase Chain Reaction | 18 | 2015 | 6086 | 0.450 |
Why?
|
| Life Style | 3 | 2023 | 3931 | 0.450 |
Why?
|
| Receptors, Androgen | 5 | 2020 | 1091 | 0.440 |
Why?
|
| Body Mass Index | 11 | 2021 | 13055 | 0.440 |
Why?
|
| Smoking | 12 | 2014 | 9094 | 0.440 |
Why?
|
| Aged, 80 and over | 47 | 2024 | 59739 | 0.440 |
Why?
|
| Telomere | 2 | 2017 | 943 | 0.430 |
Why?
|
| Cohort Studies | 44 | 2024 | 41808 | 0.430 |
Why?
|
| Postmenopause | 5 | 2012 | 2519 | 0.430 |
Why?
|
| Obesity | 14 | 2024 | 13091 | 0.420 |
Why?
|
| Developing Countries | 5 | 2021 | 2911 | 0.420 |
Why?
|
| Aromatase | 3 | 2011 | 147 | 0.420 |
Why?
|
| Population Groups | 3 | 2022 | 208 | 0.410 |
Why?
|
| Genetic Loci | 12 | 2020 | 2630 | 0.410 |
Why?
|
| Neoplasm Staging | 19 | 2023 | 11262 | 0.410 |
Why?
|
| Breast Neoplasms, Male | 3 | 2022 | 212 | 0.410 |
Why?
|
| Logistic Models | 18 | 2019 | 13318 | 0.400 |
Why?
|
| Mass Screening | 13 | 2024 | 5457 | 0.400 |
Why?
|
| Internationality | 1 | 2018 | 1008 | 0.400 |
Why?
|
| Neoplasm Invasiveness | 6 | 2017 | 3629 | 0.400 |
Why?
|
| DNA | 10 | 2015 | 7214 | 0.400 |
Why?
|
| General Practitioners | 1 | 2013 | 103 | 0.400 |
Why?
|
| Senegal | 7 | 2021 | 256 | 0.400 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 2 | 2008 | 56 | 0.390 |
Why?
|
| Prospective Studies | 25 | 2023 | 54962 | 0.390 |
Why?
|
| Income | 4 | 2024 | 1879 | 0.380 |
Why?
|
| Research Personnel | 2 | 2015 | 590 | 0.380 |
Why?
|
| Models, Statistical | 9 | 2020 | 5110 | 0.380 |
Why?
|
| Epidemiologic Methods | 4 | 2010 | 1328 | 0.380 |
Why?
|
| Health Promotion | 1 | 2023 | 2210 | 0.380 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 3 | 2010 | 213 | 0.370 |
Why?
|
| Public Health | 6 | 2023 | 2680 | 0.370 |
Why?
|
| Haiti | 3 | 2022 | 553 | 0.360 |
Why?
|
| Postal Service | 1 | 2011 | 96 | 0.360 |
Why?
|
| Scavenger Receptors, Class A | 2 | 2008 | 52 | 0.360 |
Why?
|
| Transcription Factors | 19 | 2015 | 12174 | 0.360 |
Why?
|
| Watchful Waiting | 3 | 2019 | 498 | 0.360 |
Why?
|
| Seminal Vesicles | 2 | 2014 | 103 | 0.350 |
Why?
|
| Computer-Assisted Instruction | 1 | 2013 | 366 | 0.350 |
Why?
|
| Models, Genetic | 7 | 2009 | 3449 | 0.350 |
Why?
|
| Penetrance | 4 | 2018 | 386 | 0.350 |
Why?
|
| Delivery of Health Care | 6 | 2023 | 5375 | 0.340 |
Why?
|
| Tumor Suppressor Proteins | 5 | 2011 | 2812 | 0.340 |
Why?
|
| Prejudice | 1 | 2014 | 574 | 0.340 |
Why?
|
| Receptors, Estrogen | 11 | 2017 | 2252 | 0.340 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 3 | 2012 | 276 | 0.330 |
Why?
|
| Paraproteinemias | 2 | 2022 | 252 | 0.330 |
Why?
|
| South Africa | 8 | 2023 | 1872 | 0.330 |
Why?
|
| Androgen Antagonists | 3 | 2023 | 1421 | 0.320 |
Why?
|
| Perimenopause | 1 | 2010 | 142 | 0.320 |
Why?
|
| Oncogene Proteins | 2 | 2020 | 718 | 0.320 |
Why?
|
| Decision Trees | 1 | 2011 | 509 | 0.320 |
Why?
|
| Reproductive History | 3 | 2014 | 210 | 0.320 |
Why?
|
| Membrane Transport Proteins | 2 | 2006 | 1038 | 0.320 |
Why?
|
| Urban Population | 1 | 2017 | 2046 | 0.320 |
Why?
|
| Phenotype | 27 | 2020 | 16731 | 0.310 |
Why?
|
| Group Processes | 1 | 2010 | 228 | 0.310 |
Why?
|
| Alopecia | 1 | 2013 | 416 | 0.310 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2008 | 66 | 0.300 |
Why?
|
| Genetic Counseling | 5 | 2020 | 634 | 0.300 |
Why?
|
| Education, Medical, Continuing | 1 | 2013 | 829 | 0.300 |
Why?
|
| Environmental Exposure | 4 | 2020 | 4544 | 0.300 |
Why?
|
| Intermediate Filament Proteins | 3 | 2014 | 262 | 0.300 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2011 | 1560 | 0.290 |
Why?
|
| Medical Oncology | 5 | 2023 | 2350 | 0.290 |
Why?
|
| Progestins | 2 | 2007 | 302 | 0.290 |
Why?
|
| National Cancer Institute (U.S.) | 5 | 2023 | 300 | 0.290 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2008 | 410 | 0.290 |
Why?
|
| North America | 7 | 2012 | 1290 | 0.290 |
Why?
|
| Science | 1 | 2010 | 236 | 0.290 |
Why?
|
| Follow-Up Studies | 21 | 2023 | 39394 | 0.280 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2018 | 2251 | 0.280 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2010 | 329 | 0.280 |
Why?
|
| Phytoestrogens | 1 | 2007 | 59 | 0.280 |
Why?
|
| Patient Preference | 2 | 2024 | 947 | 0.280 |
Why?
|
| Social Support | 1 | 2017 | 2193 | 0.280 |
Why?
|
| Eye Color | 3 | 2006 | 35 | 0.270 |
Why?
|
| Disease-Free Survival | 8 | 2020 | 6856 | 0.270 |
Why?
|
| Pedigree | 24 | 2017 | 4545 | 0.270 |
Why?
|
| Geography | 4 | 2018 | 654 | 0.270 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2011 | 465 | 0.270 |
Why?
|
| Caribbean Region | 3 | 2022 | 193 | 0.260 |
Why?
|
| Africa | 5 | 2024 | 726 | 0.260 |
Why?
|
| Organic Anion Transporters | 1 | 2006 | 101 | 0.260 |
Why?
|
| Salpingectomy | 2 | 2016 | 45 | 0.260 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 2 | 2011 | 74 | 0.260 |
Why?
|
| Ribosomal Proteins | 1 | 2008 | 370 | 0.260 |
Why?
|
| Europe | 6 | 2019 | 3441 | 0.260 |
Why?
|
| Interdisciplinary Communication | 3 | 2010 | 937 | 0.260 |
Why?
|
| DNA Mutational Analysis | 9 | 2010 | 4124 | 0.260 |
Why?
|
| Dermatitis, Atopic | 4 | 2014 | 737 | 0.250 |
Why?
|
| Ubiquitin-Protein Ligases | 3 | 2011 | 1902 | 0.250 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2022 | 2044 | 0.250 |
Why?
|
| Membrane Proteins | 6 | 2015 | 7885 | 0.250 |
Why?
|
| Arylamine N-Acetyltransferase | 3 | 2004 | 87 | 0.250 |
Why?
|
| Multigene Family | 2 | 2020 | 1082 | 0.250 |
Why?
|
| DNA Repair | 6 | 2021 | 2054 | 0.250 |
Why?
|
| Androgens | 2 | 2013 | 1285 | 0.240 |
Why?
|
| Mendelian Randomization Analysis | 3 | 2020 | 1040 | 0.240 |
Why?
|
| Biopsy | 6 | 2023 | 6805 | 0.240 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2021 | 8664 | 0.240 |
Why?
|
| Penicillins | 1 | 2008 | 406 | 0.240 |
Why?
|
| Phytotherapy | 1 | 2007 | 298 | 0.240 |
Why?
|
| Promoter Regions, Genetic | 3 | 2021 | 5801 | 0.240 |
Why?
|
| Chromosomes, Human, Pair 11 | 5 | 2016 | 411 | 0.240 |
Why?
|
| Confidence Intervals | 8 | 2013 | 2932 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 6 | 2024 | 7460 | 0.240 |
Why?
|
| Age Factors | 21 | 2022 | 18435 | 0.230 |
Why?
|
| Acetyltransferases | 1 | 2005 | 231 | 0.230 |
Why?
|
| Algorithms | 10 | 2018 | 14201 | 0.230 |
Why?
|
| Prostatic Hyperplasia | 1 | 2008 | 523 | 0.230 |
Why?
|
| Interleukin-4 | 1 | 2008 | 1157 | 0.230 |
Why?
|
| Cross-Sectional Studies | 15 | 2024 | 26395 | 0.230 |
Why?
|
| Neoplasms, Multiple Primary | 6 | 2007 | 592 | 0.230 |
Why?
|
| Proto-Oncogenes | 3 | 2001 | 322 | 0.230 |
Why?
|
| Sunlight | 4 | 2010 | 337 | 0.220 |
Why?
|
| Tobacco Use Disorder | 1 | 2009 | 708 | 0.220 |
Why?
|
| Genome, Human | 11 | 2020 | 4456 | 0.220 |
Why?
|
| Peritoneal Neoplasms | 2 | 2018 | 714 | 0.220 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 2784 | 0.220 |
Why?
|
| Interleukin-10 | 2 | 2008 | 1183 | 0.220 |
Why?
|
| Biological Products | 1 | 2013 | 947 | 0.220 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2024 | 211 | 0.220 |
Why?
|
| Trinucleotide Repeats | 3 | 2011 | 257 | 0.220 |
Why?
|
| Guideline Adherence | 1 | 2013 | 2241 | 0.210 |
Why?
|
| Pharmacogenetics | 1 | 2007 | 683 | 0.210 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2006 | 658 | 0.210 |
Why?
|
| Polymorphism, Restriction Fragment Length | 7 | 2011 | 767 | 0.210 |
Why?
|
| Eating | 1 | 2010 | 1542 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 15 | 2 | 2002 | 361 | 0.210 |
Why?
|
| DNA-Binding Proteins | 11 | 2014 | 9618 | 0.210 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2003 | 109 | 0.210 |
Why?
|
| Antiporters | 3 | 1993 | 276 | 0.210 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2023 | 3671 | 0.210 |
Why?
|
| Body Height | 2 | 2019 | 1569 | 0.210 |
Why?
|
| Telomerase | 3 | 2013 | 753 | 0.210 |
Why?
|
| Skin Pigmentation | 5 | 2015 | 281 | 0.200 |
Why?
|
| Young Adult | 22 | 2022 | 60131 | 0.200 |
Why?
|
| Proportional Hazards Models | 11 | 2021 | 12562 | 0.200 |
Why?
|
| Skin Diseases | 1 | 2011 | 1085 | 0.200 |
Why?
|
| Retrospective Studies | 26 | 2024 | 81903 | 0.200 |
Why?
|
| Age of Onset | 8 | 2015 | 3346 | 0.200 |
Why?
|
| Genetic Techniques | 1 | 2005 | 428 | 0.200 |
Why?
|
| Serine Endopeptidases | 2 | 2021 | 1027 | 0.200 |
Why?
|
| Health Policy | 2 | 2021 | 2700 | 0.190 |
Why?
|
| Prevalence | 12 | 2022 | 15879 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 17 | 6 | 2011 | 419 | 0.190 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2001 | 414 | 0.190 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 1 | 2021 | 72 | 0.190 |
Why?
|
| DNA Repair-Deficiency Disorders | 1 | 2021 | 37 | 0.190 |
Why?
|
| Sulfotransferases | 3 | 2010 | 150 | 0.190 |
Why?
|
| Rwanda | 2 | 2022 | 673 | 0.190 |
Why?
|
| Carrier Proteins | 6 | 2015 | 4939 | 0.190 |
Why?
|
| Receptors, Immunologic | 2 | 2005 | 1418 | 0.190 |
Why?
|
| Genetic Heterogeneity | 3 | 2007 | 737 | 0.190 |
Why?
|
| Pigmentation | 1 | 2002 | 143 | 0.190 |
Why?
|
| Privacy | 1 | 2023 | 233 | 0.190 |
Why?
|
| Agouti Signaling Protein | 3 | 2014 | 23 | 0.190 |
Why?
|
| Transforming Growth Factor beta | 2 | 2010 | 2004 | 0.190 |
Why?
|
| Cancer Care Facilities | 1 | 2024 | 428 | 0.190 |
Why?
|
| Inflammation | 4 | 2023 | 10868 | 0.190 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2005 | 647 | 0.180 |
Why?
|
| Tumor Microenvironment | 5 | 2022 | 3952 | 0.180 |
Why?
|
| Treatment Failure | 3 | 2015 | 2664 | 0.180 |
Why?
|
| Decision Support Techniques | 1 | 2011 | 2008 | 0.180 |
Why?
|
| Predictive Value of Tests | 11 | 2022 | 15471 | 0.180 |
Why?
|
| Neoplasms, Glandular and Epithelial | 2 | 2015 | 489 | 0.180 |
Why?
|
| New South Wales | 2 | 2013 | 69 | 0.180 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2014 | 1093 | 0.180 |
Why?
|
| Likelihood Functions | 4 | 2015 | 994 | 0.180 |
Why?
|
| Access to Information | 1 | 2023 | 317 | 0.180 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2023 | 2960 | 0.180 |
Why?
|
| Hydroxytestosterones | 1 | 2000 | 4 | 0.180 |
Why?
|
| Albinism, Ocular | 2 | 1997 | 7 | 0.170 |
Why?
|
| Probability | 9 | 2009 | 2483 | 0.170 |
Why?
|
| Survival Rate | 10 | 2021 | 12873 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 19 | 2 | 2012 | 350 | 0.170 |
Why?
|
| Loss of Heterozygosity | 5 | 2016 | 663 | 0.170 |
Why?
|
| Lymphoma, B-Cell | 1 | 2006 | 945 | 0.170 |
Why?
|
| Hormone Replacement Therapy | 1 | 2005 | 757 | 0.170 |
Why?
|
| Pancreatic Neoplasms | 3 | 2022 | 5443 | 0.170 |
Why?
|
| Rad51 Recombinase | 3 | 2011 | 191 | 0.170 |
Why?
|
| Biological Specimen Banks | 2 | 2022 | 789 | 0.170 |
Why?
|
| Databases, Nucleic Acid | 1 | 2020 | 204 | 0.170 |
Why?
|
| Women's Health | 2 | 2017 | 2081 | 0.170 |
Why?
|
| Oxidoreductases | 1 | 2002 | 412 | 0.170 |
Why?
|
| Exons | 7 | 2016 | 2395 | 0.160 |
Why?
|
| Repressor Proteins | 4 | 2020 | 2986 | 0.160 |
Why?
|
| Drug Hypersensitivity | 1 | 2008 | 923 | 0.160 |
Why?
|
| Podophyllotoxin | 1 | 1998 | 20 | 0.160 |
Why?
|
| Biopsy, Needle | 2 | 2013 | 1626 | 0.160 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2021 | 835 | 0.160 |
Why?
|
| Databases, Genetic | 3 | 2019 | 1758 | 0.160 |
Why?
|
| Meta-Analysis as Topic | 5 | 2018 | 1364 | 0.160 |
Why?
|
| Trans-Activators | 3 | 2015 | 2858 | 0.160 |
Why?
|
| Choice Behavior | 1 | 2024 | 848 | 0.160 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2005 | 1658 | 0.150 |
Why?
|
| Linkage Disequilibrium | 10 | 2013 | 2000 | 0.150 |
Why?
|
| Obesity, Abdominal | 1 | 2021 | 375 | 0.150 |
Why?
|
| Neuropeptide Y | 1 | 2019 | 194 | 0.150 |
Why?
|
| Adenocarcinoma | 4 | 2019 | 6401 | 0.150 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2006 | 1943 | 0.150 |
Why?
|
| Carcinogens, Environmental | 2 | 2004 | 70 | 0.150 |
Why?
|
| Glutathione S-Transferase pi | 4 | 2015 | 99 | 0.150 |
Why?
|
| Methotrexate | 1 | 2005 | 1723 | 0.150 |
Why?
|
| Baltimore | 1 | 2018 | 233 | 0.150 |
Why?
|
| Gene Deletion | 4 | 2011 | 2674 | 0.150 |
Why?
|
| Age Distribution | 5 | 2020 | 2875 | 0.150 |
Why?
|
| Australia | 6 | 2023 | 1265 | 0.150 |
Why?
|
| Hair Color | 3 | 2010 | 131 | 0.150 |
Why?
|
| Kenya | 1 | 2020 | 758 | 0.150 |
Why?
|
| Chromosomal Instability | 1 | 2018 | 176 | 0.150 |
Why?
|
| Feeding Behavior | 1 | 2010 | 3205 | 0.140 |
Why?
|
| Phenylthiohydantoin | 1 | 2019 | 215 | 0.140 |
Why?
|
| Menopause | 3 | 2019 | 1656 | 0.140 |
Why?
|
| Botswana | 4 | 2022 | 1065 | 0.140 |
Why?
|
| Stress, Psychological | 1 | 2013 | 4530 | 0.140 |
Why?
|
| Leukemia | 3 | 2024 | 1520 | 0.140 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2012 | 708 | 0.140 |
Why?
|
| Travel | 1 | 2023 | 805 | 0.140 |
Why?
|
| Genital Neoplasms, Female | 1 | 2022 | 538 | 0.140 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2003 | 1064 | 0.140 |
Why?
|
| Morbidity | 2 | 2013 | 1757 | 0.140 |
Why?
|
| Founder Effect | 3 | 2012 | 185 | 0.130 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2006 | 1437 | 0.130 |
Why?
|
| Mouth Mucosa | 1 | 1999 | 437 | 0.130 |
Why?
|
| Informed Consent | 1 | 2023 | 1010 | 0.130 |
Why?
|
| Disease Progression | 10 | 2021 | 13674 | 0.130 |
Why?
|
| Multifactorial Inheritance | 3 | 2022 | 1423 | 0.130 |
Why?
|
| X Chromosome | 2 | 1997 | 819 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 16 | 4 | 2013 | 344 | 0.130 |
Why?
|
| Markov Chains | 1 | 2020 | 979 | 0.130 |
Why?
|
| Health Status | 2 | 2006 | 4095 | 0.130 |
Why?
|
| Sex Distribution | 3 | 2018 | 2280 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2024 | 2508 | 0.130 |
Why?
|
| Pandemics | 4 | 2024 | 8749 | 0.130 |
Why?
|
| Tanzania | 1 | 2020 | 1407 | 0.130 |
Why?
|
| Cholesterol, HDL | 2 | 2020 | 1820 | 0.130 |
Why?
|
| ROC Curve | 4 | 2023 | 3629 | 0.130 |
Why?
|
| Adolescent | 23 | 2020 | 89244 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 2 | 2006 | 1060 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2016 | 323 | 0.130 |
Why?
|
| Glucuronosyltransferase | 2 | 2006 | 136 | 0.120 |
Why?
|
| Advisory Committees | 1 | 2019 | 797 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2023 | 6547 | 0.120 |
Why?
|
| Chromosome Mapping | 10 | 2017 | 4625 | 0.120 |
Why?
|
| Genes, Mitochondrial | 1 | 2015 | 59 | 0.120 |
Why?
|
| Decision Making | 4 | 2020 | 3953 | 0.120 |
Why?
|
| Immunohistochemistry | 7 | 2021 | 11116 | 0.120 |
Why?
|
| Carcinoma, Lobular | 2 | 2014 | 480 | 0.120 |
Why?
|
| Life Expectancy | 1 | 2022 | 1249 | 0.120 |
Why?
|
| Bayes Theorem | 4 | 2018 | 2360 | 0.120 |
Why?
|
| Hypertension | 7 | 2014 | 8617 | 0.120 |
Why?
|
| Individuality | 1 | 1996 | 307 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2007 | 710 | 0.120 |
Why?
|
| Bone Marrow Cells | 1 | 2002 | 2414 | 0.120 |
Why?
|
| Preventive Health Services | 1 | 2019 | 570 | 0.120 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1998 | 622 | 0.120 |
Why?
|
| Specimen Handling | 1 | 1999 | 708 | 0.120 |
Why?
|
| Sensitivity and Specificity | 8 | 2022 | 14752 | 0.120 |
Why?
|
| Stromal Cells | 1 | 2020 | 1337 | 0.120 |
Why?
|
| Monte Carlo Method | 1 | 2020 | 1262 | 0.110 |
Why?
|
| Mass Spectrometry | 2 | 2022 | 2204 | 0.110 |
Why?
|
| Nuclear Receptor Coactivator 3 | 2 | 2005 | 46 | 0.110 |
Why?
|
| Interleukin-16 | 1 | 2013 | 34 | 0.110 |
Why?
|
| Dietary Supplements | 1 | 2007 | 3443 | 0.110 |
Why?
|
| Psychology | 1 | 2016 | 354 | 0.110 |
Why?
|
| Proteins | 3 | 2013 | 6011 | 0.110 |
Why?
|
| Diet | 2 | 2022 | 8088 | 0.110 |
Why?
|
| Ghana | 3 | 2021 | 333 | 0.110 |
Why?
|
| Smoking Cessation | 1 | 2005 | 2085 | 0.110 |
Why?
|
| Receptor, erbB-2 | 4 | 2014 | 2606 | 0.110 |
Why?
|
| Selection, Genetic | 1 | 2018 | 878 | 0.110 |
Why?
|
| Reference Values | 3 | 2010 | 4940 | 0.110 |
Why?
|
| DNA Glycosylases | 1 | 2014 | 125 | 0.110 |
Why?
|
| Family | 3 | 2018 | 3208 | 0.110 |
Why?
|
| Parasites | 1 | 2015 | 160 | 0.110 |
Why?
|
| S100 Proteins | 1 | 2013 | 217 | 0.110 |
Why?
|
| Maternal Age | 2 | 2014 | 805 | 0.100 |
Why?
|
| Directive Counseling | 1 | 2014 | 171 | 0.100 |
Why?
|
| Reproducibility of Results | 10 | 2014 | 20245 | 0.100 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2012 | 558 | 0.100 |
Why?
|
| Clubfoot | 1 | 1993 | 87 | 0.100 |
Why?
|
| Fungi | 1 | 2015 | 345 | 0.100 |
Why?
|
| Educational Status | 2 | 2023 | 2515 | 0.100 |
Why?
|
| Progesterone | 2 | 2007 | 752 | 0.100 |
Why?
|
| Triglycerides | 1 | 2020 | 2464 | 0.100 |
Why?
|
| Cytochrome P-450 CYP1A1 | 2 | 2006 | 88 | 0.100 |
Why?
|
| Nucleotides | 1 | 2015 | 455 | 0.100 |
Why?
|
| Contraceptives, Oral | 4 | 2014 | 561 | 0.100 |
Why?
|
| Multivariate Analysis | 5 | 2016 | 12095 | 0.100 |
Why?
|
| DNA Primers | 4 | 2007 | 2827 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 8 | 3 | 2011 | 453 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 6 | 4 | 2016 | 370 | 0.100 |
Why?
|
| Chromosomes, Human | 2 | 2011 | 438 | 0.100 |
Why?
|
| Proteomics | 2 | 2017 | 3914 | 0.100 |
Why?
|
| Metformin | 1 | 2020 | 909 | 0.100 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 4926 | 0.100 |
Why?
|
| Registries | 6 | 2023 | 8384 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2024 | 8748 | 0.100 |
Why?
|
| Homozygote | 3 | 2013 | 1780 | 0.100 |
Why?
|
| Epistasis, Genetic | 2 | 2011 | 353 | 0.100 |
Why?
|
| Attitude to Health | 2 | 2019 | 2025 | 0.100 |
Why?
|
| Lymphatic Metastasis | 4 | 2010 | 2916 | 0.100 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 2276 | 0.100 |
Why?
|
| Viruses | 1 | 2015 | 373 | 0.100 |
Why?
|
| Depression | 2 | 2012 | 8231 | 0.090 |
Why?
|
| India | 2 | 2008 | 2334 | 0.090 |
Why?
|
| Polychondritis, Relapsing | 1 | 2011 | 29 | 0.090 |
Why?
|
| Osteogenesis Imperfecta | 1 | 2012 | 81 | 0.090 |
Why?
|
| Research Report | 1 | 2014 | 369 | 0.090 |
Why?
|
| Caspase 10 | 1 | 2010 | 3 | 0.090 |
Why?
|
| Linear Models | 3 | 2017 | 5891 | 0.090 |
Why?
|
| Neuroblastoma | 4 | 2002 | 1266 | 0.090 |
Why?
|
| Severity of Illness Index | 4 | 2017 | 15951 | 0.090 |
Why?
|
| Data Mining | 2 | 2019 | 563 | 0.090 |
Why?
|
| Family Health | 5 | 2008 | 1255 | 0.090 |
Why?
|
| Transcription, Genetic | 2 | 2015 | 7609 | 0.090 |
Why?
|
| Disease Susceptibility | 6 | 2022 | 1794 | 0.090 |
Why?
|
| Luciferases | 3 | 2013 | 713 | 0.090 |
Why?
|
| Cholesterol, LDL | 1 | 2020 | 2403 | 0.090 |
Why?
|
| Interviews as Topic | 2 | 2010 | 2744 | 0.090 |
Why?
|
| Survival Analysis | 6 | 2019 | 10115 | 0.090 |
Why?
|
| Base Sequence | 6 | 2011 | 12430 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2012 | 432 | 0.090 |
Why?
|
| Smad3 Protein | 1 | 2010 | 166 | 0.090 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 2 | 2011 | 781 | 0.090 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2011 | 131 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 2911 | 0.090 |
Why?
|
| Sex Factors | 4 | 2013 | 10633 | 0.090 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2013 | 277 | 0.090 |
Why?
|
| Caspase 8 | 1 | 2010 | 198 | 0.090 |
Why?
|
| Gene Pool | 1 | 2009 | 36 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2023 | 4056 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2012 | 534 | 0.090 |
Why?
|
| Aspirin | 1 | 2021 | 3135 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2023 | 3628 | 0.080 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2011 | 271 | 0.080 |
Why?
|
| Quality of Life | 4 | 2019 | 13510 | 0.080 |
Why?
|
| HIV Infections | 3 | 2022 | 17591 | 0.080 |
Why?
|
| Gene Amplification | 1 | 1994 | 1099 | 0.080 |
Why?
|
| Organizational Objectives | 2 | 2008 | 426 | 0.080 |
Why?
|
| Models, Biological | 3 | 2018 | 9499 | 0.080 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2009 | 67 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 2 | 2009 | 2714 | 0.080 |
Why?
|
| Research Design | 5 | 2019 | 6214 | 0.080 |
Why?
|
| Point Mutation | 2 | 2008 | 1596 | 0.080 |
Why?
|
| Statistics, Nonparametric | 2 | 2008 | 2862 | 0.080 |
Why?
|
| Quantitative Trait Loci | 4 | 2020 | 2133 | 0.080 |
Why?
|
| Child, Preschool | 13 | 2013 | 42683 | 0.080 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2009 | 98 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2018 | 2884 | 0.080 |
Why?
|
| Genes, Reporter | 3 | 2015 | 1524 | 0.080 |
Why?
|
| DNA Methylation | 2 | 2021 | 4432 | 0.080 |
Why?
|
| Keratosis | 1 | 2009 | 81 | 0.080 |
Why?
|
| Knowledge Bases | 1 | 2009 | 97 | 0.080 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2007 | 388 | 0.080 |
Why?
|
| Amino Acid Substitution | 3 | 2009 | 1742 | 0.080 |
Why?
|
| Trinidad and Tobago | 2 | 2018 | 13 | 0.080 |
Why?
|
| Breast Feeding | 1 | 2017 | 1364 | 0.080 |
Why?
|
| Diabetes Complications | 2 | 2014 | 1320 | 0.080 |
Why?
|
| Chromosomes, Human, Y | 1 | 2009 | 164 | 0.080 |
Why?
|
| Proteoglycans | 1 | 2012 | 809 | 0.080 |
Why?
|
| History, 20th Century | 2 | 2020 | 2771 | 0.080 |
Why?
|
| Salpingostomy | 1 | 2008 | 8 | 0.080 |
Why?
|
| RNA Helicases | 1 | 2009 | 144 | 0.080 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2011 | 794 | 0.080 |
Why?
|
| Mortality | 1 | 2020 | 2914 | 0.080 |
Why?
|
| Somatomedins | 1 | 2009 | 179 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2022 | 6002 | 0.080 |
Why?
|
| Time Factors | 7 | 2019 | 40261 | 0.080 |
Why?
|
| DNA, Neoplasm | 5 | 2010 | 1748 | 0.080 |
Why?
|
| Delayed Graft Function | 1 | 2008 | 50 | 0.080 |
Why?
|
| Occupational Exposure | 3 | 2014 | 1807 | 0.080 |
Why?
|
| Endodeoxyribonucleases | 1 | 2009 | 166 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 8055 | 0.080 |
Why?
|
| Lead | 1 | 2014 | 882 | 0.080 |
Why?
|
| Leukemia, Myeloid | 3 | 2001 | 693 | 0.080 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2012 | 411 | 0.070 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2008 | 131 | 0.070 |
Why?
|
| Treatment Outcome | 12 | 2021 | 65480 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2009 | 208 | 0.070 |
Why?
|
| Child | 19 | 2022 | 80960 | 0.070 |
Why?
|
| Social Medicine | 1 | 2008 | 64 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 8 | 2015 | 4785 | 0.070 |
Why?
|
| Uterine Neoplasms | 1 | 2016 | 1424 | 0.070 |
Why?
|
| Cimicifuga | 1 | 2007 | 4 | 0.070 |
Why?
|
| RNA Interference | 2 | 2013 | 2835 | 0.070 |
Why?
|
| Epidemiologic Research Design | 1 | 2011 | 368 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2020 | 12806 | 0.070 |
Why?
|
| DNA Repair Enzymes | 1 | 2009 | 346 | 0.070 |
Why?
|
| Gene Expression Profiling | 5 | 2021 | 9549 | 0.070 |
Why?
|
| Brachial Plexus Neuritis | 2 | 1997 | 21 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2015 | 3810 | 0.070 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2009 | 249 | 0.070 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 1769 | 0.070 |
Why?
|
| Deafness | 1 | 2011 | 462 | 0.070 |
Why?
|
| Meat | 1 | 2010 | 588 | 0.070 |
Why?
|
| Aromatase Inhibitors | 1 | 2011 | 519 | 0.070 |
Why?
|
| Radiation Injuries | 1 | 2014 | 1203 | 0.070 |
Why?
|
| Arthralgia | 1 | 2011 | 459 | 0.070 |
Why?
|
| Nevus, Pigmented | 1 | 2009 | 222 | 0.070 |
Why?
|
| Educational Measurement | 1 | 2013 | 1260 | 0.070 |
Why?
|
| Ambulatory Care Facilities | 2 | 2022 | 941 | 0.070 |
Why?
|
| beta-Lactamases | 1 | 2008 | 307 | 0.070 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2020 | 1120 | 0.070 |
Why?
|
| Regression Analysis | 5 | 2016 | 6346 | 0.060 |
Why?
|
| Heredity | 2 | 2017 | 149 | 0.060 |
Why?
|
| Nuclear Proteins | 4 | 2020 | 5804 | 0.060 |
Why?
|
| Arthritis | 1 | 2011 | 684 | 0.060 |
Why?
|
| Cyclophosphamide | 2 | 2010 | 2227 | 0.060 |
Why?
|
| Glutathione Peroxidase | 1 | 2006 | 259 | 0.060 |
Why?
|
| Evolution, Molecular | 3 | 2015 | 1894 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 2460 | 0.060 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2005 | 106 | 0.060 |
Why?
|
| Authorship | 1 | 2008 | 289 | 0.060 |
Why?
|
| Guidelines as Topic | 2 | 2013 | 1399 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 10 | 4 | 2011 | 277 | 0.060 |
Why?
|
| Genes, p16 | 1 | 2005 | 159 | 0.060 |
Why?
|
| Peer Review, Research | 1 | 2008 | 344 | 0.060 |
Why?
|
| Computational Biology | 4 | 2015 | 3562 | 0.060 |
Why?
|
| Poverty | 1 | 2017 | 2720 | 0.060 |
Why?
|
| Sequence Deletion | 2 | 2011 | 1498 | 0.060 |
Why?
|
| Genetic Diseases, Inborn | 2 | 2003 | 606 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 3253 | 0.060 |
Why?
|
| Receptors, Scavenger | 1 | 2005 | 123 | 0.060 |
Why?
|
| Fanconi Anemia | 2 | 2021 | 327 | 0.060 |
Why?
|
| Bioethics | 1 | 2006 | 118 | 0.060 |
Why?
|
| Ultraviolet Rays | 2 | 2007 | 1104 | 0.060 |
Why?
|
| Bacteria | 1 | 2015 | 2216 | 0.060 |
Why?
|
| Fruit | 1 | 2010 | 1165 | 0.060 |
Why?
|
| Fertility | 1 | 2009 | 771 | 0.060 |
Why?
|
| Vegetables | 1 | 2010 | 1199 | 0.060 |
Why?
|
| Proteome | 1 | 2014 | 1891 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 2525 | 0.060 |
Why?
|
| Cultural Characteristics | 1 | 2005 | 250 | 0.060 |
Why?
|
| Transfection | 2 | 2021 | 5763 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 1 | 3 | 2011 | 640 | 0.060 |
Why?
|
| Tamoxifen | 1 | 2008 | 967 | 0.060 |
Why?
|
| Histones | 1 | 2014 | 2603 | 0.060 |
Why?
|
| Disease | 1 | 2009 | 673 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2024 | 2848 | 0.060 |
Why?
|
| Histone Acetyltransferases | 1 | 2005 | 335 | 0.050 |
Why?
|
| Los Angeles | 1 | 2024 | 245 | 0.050 |
Why?
|
| Longitudinal Studies | 4 | 2016 | 14794 | 0.050 |
Why?
|
| Demography | 1 | 2008 | 1642 | 0.050 |
Why?
|
| Plant Extracts | 1 | 2007 | 499 | 0.050 |
Why?
|
| Gene Rearrangement | 1 | 2008 | 1148 | 0.050 |
Why?
|
| Mastectomy, Segmental | 2 | 2006 | 960 | 0.050 |
Why?
|
| Cell Line, Tumor | 4 | 2015 | 17173 | 0.050 |
Why?
|
| DNA Topoisomerases, Type II | 2 | 2001 | 121 | 0.050 |
Why?
|
| Lod Score | 4 | 1998 | 600 | 0.050 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2007 | 542 | 0.050 |
Why?
|
| Kidney Transplantation | 2 | 2008 | 4265 | 0.050 |
Why?
|
| Control Groups | 1 | 2003 | 107 | 0.050 |
Why?
|
| Acyltransferases | 1 | 2004 | 306 | 0.050 |
Why?
|
| Membrane Glycoproteins | 2 | 2012 | 3713 | 0.050 |
Why?
|
| Melanocytes | 2 | 2004 | 509 | 0.050 |
Why?
|
| Cell Cycle Proteins | 2 | 2015 | 3450 | 0.050 |
Why?
|
| Receptors, Erythropoietin | 1 | 2002 | 144 | 0.050 |
Why?
|
| Risk Management | 1 | 2006 | 558 | 0.050 |
Why?
|
| Cholestenone 5 alpha-Reductase | 1 | 2002 | 21 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2008 | 980 | 0.050 |
Why?
|
| Osteoporosis | 1 | 2012 | 1606 | 0.050 |
Why?
|
| Cell Line | 3 | 2011 | 15604 | 0.050 |
Why?
|
| Epidemiologic Factors | 1 | 2002 | 36 | 0.050 |
Why?
|
| Carcinogens | 1 | 2004 | 453 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 2 | 2008 | 2228 | 0.050 |
Why?
|
| Isoenzymes | 2 | 2004 | 1687 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 3 | 2007 | 1629 | 0.050 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 3 | 2001 | 308 | 0.050 |
Why?
|
| Clothing | 1 | 2002 | 96 | 0.050 |
Why?
|
| Data Collection | 1 | 2011 | 3324 | 0.050 |
Why?
|
| beta-Galactosidase | 1 | 2003 | 575 | 0.050 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2022 | 289 | 0.050 |
Why?
|
| Human Experimentation | 1 | 2002 | 125 | 0.050 |
Why?
|
| Forecasting | 3 | 2004 | 2945 | 0.050 |
Why?
|
| Hematoxylin | 1 | 2021 | 61 | 0.050 |
Why?
|
| Insurance Claim Review | 1 | 2006 | 746 | 0.050 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2021 | 70 | 0.050 |
Why?
|
| Aging | 3 | 2012 | 8745 | 0.050 |
Why?
|
| Exercise | 1 | 2018 | 5954 | 0.050 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2002 | 239 | 0.050 |
Why?
|
| Molecular Biology | 1 | 2004 | 573 | 0.050 |
Why?
|
| Medical History Taking | 1 | 2005 | 779 | 0.050 |
Why?
|
| Gene Expression | 4 | 2021 | 7603 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2002 | 387 | 0.040 |
Why?
|
| Leukemia, Lymphoid | 1 | 2001 | 312 | 0.040 |
Why?
|
| Minority Groups | 2 | 2024 | 1216 | 0.040 |
Why?
|
| Sample Size | 3 | 2014 | 848 | 0.040 |
Why?
|
| Chromosome Breakage | 1 | 2001 | 159 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2024 | 890 | 0.040 |
Why?
|
| Waist-Hip Ratio | 1 | 2021 | 520 | 0.040 |
Why?
|
| Molecular Sequence Data | 4 | 2001 | 17629 | 0.040 |
Why?
|
| Nicotine | 1 | 2005 | 680 | 0.040 |
Why?
|
| Research Subjects | 1 | 2002 | 249 | 0.040 |
Why?
|
| Histone-Lysine N-Methyltransferase | 3 | 2001 | 701 | 0.040 |
Why?
|
| Graft Survival | 2 | 2008 | 3888 | 0.040 |
Why?
|
| Survivors | 1 | 2011 | 2383 | 0.040 |
Why?
|
| Technology | 1 | 2022 | 296 | 0.040 |
Why?
|
| International Agencies | 2 | 2014 | 244 | 0.040 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2022 | 219 | 0.040 |
Why?
|
| Chromosome Deletion | 2 | 2004 | 1390 | 0.040 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 2 | 2016 | 195 | 0.040 |
Why?
|
| Karyotyping | 2 | 1998 | 1177 | 0.040 |
Why?
|
| Cause of Death | 1 | 2010 | 3721 | 0.040 |
Why?
|
| Massachusetts | 2 | 2024 | 8894 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2001 | 615 | 0.040 |
Why?
|
| Menarche | 2 | 2014 | 538 | 0.040 |
Why?
|
| AMP Deaminase | 1 | 1999 | 5 | 0.040 |
Why?
|
| Self Concept | 1 | 2005 | 1046 | 0.040 |
Why?
|
| Italy | 3 | 2006 | 856 | 0.040 |
Why?
|
| Africa, Northern | 1 | 2019 | 86 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 13 | 2 | 1997 | 192 | 0.040 |
Why?
|
| Homeodomain Proteins | 2 | 2022 | 2431 | 0.040 |
Why?
|
| Cheek | 1 | 1999 | 66 | 0.040 |
Why?
|
| Etoposide | 1 | 2001 | 639 | 0.040 |
Why?
|
| Hospitalization | 1 | 2019 | 10847 | 0.040 |
Why?
|
| Confidentiality | 1 | 2023 | 606 | 0.040 |
Why?
|
| Functional Laterality | 1 | 2006 | 2267 | 0.040 |
Why?
|
| Ligases | 1 | 2000 | 333 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 13698 | 0.040 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2015 | 1305 | 0.040 |
Why?
|
| Middle East | 1 | 2019 | 233 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2001 | 588 | 0.040 |
Why?
|
| Trust | 1 | 2023 | 532 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2006 | 1839 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2021 | 432 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 2005 | 1541 | 0.040 |
Why?
|
| Recurrence | 3 | 2014 | 8513 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 1998 | 229 | 0.040 |
Why?
|
| Nomograms | 1 | 2020 | 236 | 0.040 |
Why?
|
| Lipoproteins, HDL | 1 | 2022 | 682 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2010 | 11886 | 0.040 |
Why?
|
| Erythropoietin | 1 | 2002 | 718 | 0.040 |
Why?
|
| Parity | 2 | 2012 | 931 | 0.040 |
Why?
|
| Research | 1 | 2006 | 1981 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2015 | 2732 | 0.040 |
Why?
|
| Translocation, Genetic | 2 | 2001 | 1395 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2021 | 935 | 0.040 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2018 | 241 | 0.040 |
Why?
|
| Sex Characteristics | 2 | 2002 | 2649 | 0.040 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2002 | 480 | 0.040 |
Why?
|
| Societies, Scientific | 1 | 2018 | 223 | 0.040 |
Why?
|
| Xenobiotics | 1 | 1997 | 71 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2013 | 3811 | 0.040 |
Why?
|
| Motivation | 2 | 2023 | 2025 | 0.040 |
Why?
|
| Delayed Diagnosis | 1 | 2021 | 468 | 0.030 |
Why?
|
| Research Support as Topic | 2 | 2014 | 696 | 0.030 |
Why?
|
| Glucose | 2 | 2022 | 4352 | 0.030 |
Why?
|
| Laboratories | 1 | 2020 | 463 | 0.030 |
Why?
|
| Commerce | 1 | 2002 | 613 | 0.030 |
Why?
|
| Musculoskeletal Diseases | 1 | 2023 | 599 | 0.030 |
Why?
|
| Quinone Reductases | 1 | 1996 | 24 | 0.030 |
Why?
|
| International Cooperation | 2 | 2014 | 1436 | 0.030 |
Why?
|
| Chromosome Banding | 1 | 1996 | 261 | 0.030 |
Why?
|
| Ethiopia | 1 | 2018 | 485 | 0.030 |
Why?
|
| Canada | 3 | 2006 | 2130 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 1996 | 108 | 0.030 |
Why?
|
| Introns | 3 | 2006 | 969 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2011 | 9384 | 0.030 |
Why?
|
| Cadherins | 1 | 2001 | 906 | 0.030 |
Why?
|
| Epoxide Hydrolases | 1 | 1996 | 122 | 0.030 |
Why?
|
| Brachial Plexus | 1 | 1997 | 173 | 0.030 |
Why?
|
| Signal Transduction | 5 | 2021 | 23653 | 0.030 |
Why?
|
| Primary Health Care | 2 | 2023 | 4748 | 0.030 |
Why?
|
| Genes, p53 | 1 | 1998 | 716 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2021 | 2631 | 0.030 |
Why?
|
| Health Plan Implementation | 1 | 2018 | 338 | 0.030 |
Why?
|
| Hepatocytes | 1 | 2003 | 1245 | 0.030 |
Why?
|
| Genetic Vectors | 2 | 2003 | 3412 | 0.030 |
Why?
|
| Stomach Neoplasms | 3 | 2018 | 1483 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2020 | 755 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2022 | 888 | 0.030 |
Why?
|
| Alternative Splicing | 2 | 2013 | 1105 | 0.030 |
Why?
|
| Minisatellite Repeats | 1 | 1996 | 164 | 0.030 |
Why?
|
| Genomic Imprinting | 1 | 1997 | 326 | 0.030 |
Why?
|
| Codon | 2 | 2009 | 599 | 0.030 |
Why?
|
| Helicobacter pylori | 1 | 2018 | 380 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2007 | 2493 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2008 | 4492 | 0.030 |
Why?
|
| Helicobacter Infections | 1 | 2018 | 390 | 0.030 |
Why?
|
| DNA Probes | 1 | 2015 | 543 | 0.030 |
Why?
|
| Racemases and Epimerases | 1 | 2015 | 114 | 0.030 |
Why?
|
| Apolipoproteins B | 1 | 1996 | 386 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2015 | 306 | 0.030 |
Why?
|
| Coenzyme A | 1 | 2014 | 39 | 0.030 |
Why?
|
| Acetyl Coenzyme A | 1 | 2014 | 74 | 0.030 |
Why?
|
| Apolipoprotein C-II | 1 | 1993 | 15 | 0.030 |
Why?
|
| Nitriles | 1 | 2019 | 990 | 0.030 |
Why?
|
| Chromatin | 2 | 2018 | 2981 | 0.030 |
Why?
|
| Ovum | 1 | 1995 | 187 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2003 | 2885 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2000 | 6236 | 0.030 |
Why?
|
| Apolipoproteins C | 1 | 1993 | 59 | 0.030 |
Why?
|
| Nevus | 2 | 2006 | 205 | 0.030 |
Why?
|
| Foundations | 1 | 2014 | 96 | 0.030 |
Why?
|
| Mammary Glands, Human | 1 | 2015 | 202 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 812 | 0.030 |
Why?
|
| Government Agencies | 1 | 2014 | 161 | 0.030 |
Why?
|
| Benzamides | 1 | 2019 | 1387 | 0.030 |
Why?
|
| Co-Repressor Proteins | 1 | 2014 | 190 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2013 | 93 | 0.030 |
Why?
|
| Cholesterol | 1 | 2022 | 2913 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2014 | 699 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 4592 | 0.030 |
Why?
|
| Genes, ras | 1 | 1996 | 665 | 0.030 |
Why?
|
| Databases, Factual | 3 | 2019 | 8094 | 0.030 |
Why?
|
| Patient Participation | 1 | 2002 | 1448 | 0.030 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2014 | 123 | 0.030 |
Why?
|
| Interleukin-3 | 1 | 2014 | 425 | 0.030 |
Why?
|
| Epigenesis, Genetic | 2 | 2017 | 3836 | 0.030 |
Why?
|
| Human Activities | 1 | 2012 | 26 | 0.030 |
Why?
|
| Ethics, Research | 1 | 2014 | 178 | 0.030 |
Why?
|
| Infant | 6 | 2012 | 36556 | 0.030 |
Why?
|
| Apoptosis | 1 | 2008 | 9527 | 0.020 |
Why?
|
| Poland | 1 | 2012 | 197 | 0.020 |
Why?
|
| Genes, Recessive | 1 | 1995 | 625 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 1993 | 305 | 0.020 |
Why?
|
| Apolipoprotein C-III | 1 | 1993 | 210 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2019 | 1506 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 2014 | 478 | 0.020 |
Why?
|
| Infant, Newborn | 5 | 2022 | 26428 | 0.020 |
Why?
|
| Retinoblastoma Protein | 1 | 2015 | 673 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2023 | 3143 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2006 | 5342 | 0.020 |
Why?
|
| Acetylation | 1 | 2014 | 1056 | 0.020 |
Why?
|
| Tubulin | 1 | 2015 | 695 | 0.020 |
Why?
|
| Counseling | 2 | 2000 | 1554 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2010 | 1151 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2019 | 4040 | 0.020 |
Why?
|
| Hysterectomy | 1 | 2016 | 866 | 0.020 |
Why?
|
| Hepatitis B Vaccines | 1 | 2012 | 178 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2022 | 2528 | 0.020 |
Why?
|
| Replication Protein A | 1 | 2011 | 54 | 0.020 |
Why?
|
| Immune System | 1 | 2016 | 800 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2011 | 294 | 0.020 |
Why?
|
| Sodium-Bicarbonate Symporters | 1 | 2010 | 30 | 0.020 |
Why?
|
| Estrogen Receptor alpha | 1 | 2015 | 581 | 0.020 |
Why?
|
| Minnesota | 1 | 1991 | 339 | 0.020 |
Why?
|
| Thiotepa | 1 | 2010 | 66 | 0.020 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2012 | 360 | 0.020 |
Why?
|
| Spermatozoa | 1 | 1995 | 632 | 0.020 |
Why?
|
| Computer Simulation | 3 | 2011 | 6291 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 1998 | 1181 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2020 | 9080 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2010 | 127 | 0.020 |
Why?
|
| Fanconi Anemia Complementation Group D2 Protein | 1 | 2011 | 148 | 0.020 |
Why?
|
| High Mobility Group Proteins | 1 | 2010 | 179 | 0.020 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2011 | 463 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 2 | 2013 | 4413 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2015 | 1074 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 6320 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2020 | 2974 | 0.020 |
Why?
|
| Animals | 5 | 2024 | 169335 | 0.020 |
Why?
|
| Genetics, Medical | 1 | 2012 | 334 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2012 | 15889 | 0.020 |
Why?
|
| Hospitals | 1 | 2023 | 3904 | 0.020 |
Why?
|
| Cancer Vaccines | 1 | 2017 | 1043 | 0.020 |
Why?
|
| Zebrafish | 1 | 2021 | 3037 | 0.020 |
Why?
|
| Overweight | 1 | 2020 | 2448 | 0.020 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2013 | 605 | 0.020 |
Why?
|
| Georgia | 1 | 2009 | 186 | 0.020 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 2009 | 81 | 0.020 |
Why?
|
| Oncogenes | 1 | 1995 | 1236 | 0.020 |
Why?
|
| ras Proteins | 1 | 2014 | 1058 | 0.020 |
Why?
|
| Delaware | 1 | 2008 | 13 | 0.020 |
Why?
|
| Pregnancy | 3 | 2020 | 30265 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 1705 | 0.020 |
Why?
|
| Nigeria | 1 | 2012 | 779 | 0.020 |
Why?
|
| Universities | 1 | 2014 | 1005 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2024 | 3626 | 0.020 |
Why?
|
| Methyltransferases | 1 | 2011 | 373 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2015 | 1625 | 0.020 |
Why?
|
| Vesicular Transport Proteins | 1 | 2010 | 377 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2014 | 1780 | 0.020 |
Why?
|
| Cytokines | 1 | 2003 | 7453 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 12253 | 0.020 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2012 | 496 | 0.020 |
Why?
|
| Phylogeny | 1 | 2015 | 2843 | 0.020 |
Why?
|
| Genome | 1 | 2015 | 1754 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 2921 | 0.020 |
Why?
|
| Embryo Implantation | 1 | 2009 | 272 | 0.020 |
Why?
|
| Interinstitutional Relations | 1 | 2008 | 236 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2020 | 3110 | 0.020 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2007 | 153 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 773 | 0.020 |
Why?
|
| Hypothyroidism | 1 | 2012 | 667 | 0.020 |
Why?
|
| DNA Damage | 2 | 2011 | 2472 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 1903 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 2001 | 13021 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2013 | 1575 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2001 | 2931 | 0.020 |
Why?
|
| Anticarcinogenic Agents | 1 | 2008 | 251 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2018 | 3968 | 0.020 |
Why?
|
| Medical Records | 1 | 2012 | 1411 | 0.020 |
Why?
|
| Testicular Neoplasms | 1 | 2012 | 808 | 0.020 |
Why?
|
| China | 1 | 2012 | 2395 | 0.020 |
Why?
|
| Heme Oxygenase-1 | 1 | 2008 | 364 | 0.020 |
Why?
|
| Mediterranean Region | 1 | 2005 | 47 | 0.020 |
Why?
|
| Endometrium | 1 | 2008 | 406 | 0.020 |
Why?
|
| Cell Cycle | 1 | 1994 | 2937 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2007 | 684 | 0.020 |
Why?
|
| Energy Metabolism | 2 | 2011 | 2905 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2017 | 2542 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2011 | 3076 | 0.020 |
Why?
|
| Hirschsprung Disease | 2 | 1997 | 163 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2013 | 1407 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2010 | 1655 | 0.020 |
Why?
|
| Cocarcinogenesis | 1 | 2004 | 49 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 6023 | 0.010 |
Why?
|
| Focus Groups | 1 | 2011 | 1462 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2008 | 642 | 0.010 |
Why?
|
| Hormones | 1 | 2008 | 870 | 0.010 |
Why?
|
| Diabetes Mellitus | 2 | 2013 | 5892 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2008 | 4356 | 0.010 |
Why?
|
| Boston | 1 | 2017 | 9377 | 0.010 |
Why?
|
| Israel | 1 | 2006 | 726 | 0.010 |
Why?
|
| Mitochondria | 1 | 2017 | 3682 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2010 | 2234 | 0.010 |
Why?
|
| Social Environment | 1 | 2008 | 1015 | 0.010 |
Why?
|
| Pediatrics | 1 | 2018 | 3628 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2014 | 8317 | 0.010 |
Why?
|
| Suppression, Genetic | 1 | 2003 | 190 | 0.010 |
Why?
|
| Medicare | 1 | 2021 | 6888 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 1536 | 0.010 |
Why?
|
| Consent Forms | 1 | 2002 | 55 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2012 | 2893 | 0.010 |
Why?
|
| Parents | 1 | 1996 | 3597 | 0.010 |
Why?
|
| Coercion | 1 | 2002 | 68 | 0.010 |
Why?
|
| Disclosure | 1 | 2008 | 755 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2002 | 283 | 0.010 |
Why?
|
| Caenorhabditis elegans | 1 | 2011 | 1469 | 0.010 |
Why?
|
| Recombination, Genetic | 2 | 1997 | 1526 | 0.010 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2001 | 58 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2002 | 378 | 0.010 |
Why?
|
| Catechols | 1 | 2001 | 63 | 0.010 |
Why?
|
| Fertilization in Vitro | 1 | 2009 | 1303 | 0.010 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 1515 | 0.010 |
Why?
|
| Quinones | 1 | 2001 | 78 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2006 | 1793 | 0.010 |
Why?
|
| Enzyme Stability | 1 | 2001 | 219 | 0.010 |
Why?
|
| Guanine | 1 | 2001 | 280 | 0.010 |
Why?
|
| Mice | 2 | 2021 | 82072 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2008 | 4835 | 0.010 |
Why?
|
| Glioma | 1 | 2014 | 3532 | 0.010 |
Why?
|
| Hemorrhagic Disorders | 1 | 1998 | 34 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2002 | 841 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 6982 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2010 | 3473 | 0.010 |
Why?
|
| Tissue Donors | 1 | 2008 | 2382 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2007 | 1970 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1998 | 326 | 0.010 |
Why?
|
| Digoxin | 1 | 1999 | 246 | 0.010 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 1999 | 115 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 2001 | 563 | 0.010 |
Why?
|
| Estrogen Antagonists | 1 | 1998 | 150 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1998 | 777 | 0.010 |
Why?
|
| Acute Disease | 2 | 1998 | 7245 | 0.010 |
Why?
|
| Adenosine Monophosphate | 1 | 1999 | 232 | 0.010 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2002 | 735 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2010 | 4045 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 2749 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2001 | 1751 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2001 | 13594 | 0.010 |
Why?
|
| Diseases in Twins | 1 | 1998 | 447 | 0.010 |
Why?
|
| Diuretics | 1 | 1999 | 614 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 1998 | 856 | 0.010 |
Why?
|
| Germany | 1 | 1998 | 883 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2007 | 3709 | 0.010 |
Why?
|
| Adenine | 1 | 2001 | 995 | 0.010 |
Why?
|
| Carcinoma in Situ | 1 | 2001 | 788 | 0.010 |
Why?
|
| Heart Failure | 1 | 1999 | 11879 | 0.010 |
Why?
|
| Sex Chromosome Aberrations | 1 | 1994 | 116 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2001 | 3775 | 0.010 |
Why?
|
| Ligands | 1 | 2001 | 3283 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 10400 | 0.010 |
Why?
|
| Kallmann Syndrome | 1 | 1994 | 142 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2001 | 6131 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 15661 | 0.010 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2001 | 933 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1998 | 1866 | 0.010 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1999 | 843 | 0.010 |
Why?
|
| Fundus Oculi | 1 | 1994 | 560 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 9213 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 1999 | 1883 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1999 | 1514 | 0.010 |
Why?
|
| Models, Theoretical | 2 | 1995 | 3580 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 2012 | 6569 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2001 | 2592 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 11521 | 0.010 |
Why?
|
| Schizophrenia | 1 | 2009 | 6987 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2001 | 13427 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2001 | 8559 | 0.000 |
Why?
|
| Causality | 1 | 1995 | 1256 | 0.000 |
Why?
|
| Hemodynamics | 1 | 1999 | 4199 | 0.000 |
Why?
|
| Statistics as Topic | 1 | 1995 | 2360 | 0.000 |
Why?
|
| Myocardium | 1 | 1999 | 4790 | 0.000 |
Why?
|
| Coronary Disease | 1 | 1999 | 5919 | 0.000 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2001 | 5434 | 0.000 |
Why?
|
| Skin | 1 | 1994 | 4506 | 0.000 |
Why?
|